National Hospital
| Use attributes for filter ! | |
| Address | Niamey, Niger |
|---|---|
| Opened | 1922 |
| Hours | Open 24 hours |
| Phone | +227 20 72 38 10 |
| Founded | 1922 |
| Function | Hospital |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2332651 |
About National Hospital
The National Hospital is a hospital in Niamey, Niger. It has 244 beds. The hospital was founded in 1922.
Where is the National Hospital
Safer brain surgery using AI possible within two years
... " If you go too small with your approach, then you risk not removing enough of the tumour, " National Hospital for Neurology and Neurosurgery consultant neurosurgeon Hani Marcus says...
When a child is shot, doctors must heal more than just bullet holes
... In the emergency room at Children s National Hospital in Washington, DC, hospital beds line the corridors as cartoons blare on television sets...
Her illness fooled celebs. The truth may be even darker
... The inquestMegan had died on 28 March 2018 at the National Hospital for Neurology and Neurosurgery in London...
New Alzheimer's drug slows disease by a third
... " The decades-long battle to find treatments that change Alzheimer s disease is changing, " Dr Cath Mummery, the clinical lead for the cognitive-disorders clinic at the UK s National Hospital for Neurology and Neurosurgery, said...
'Major moment in MS research' as new Octopus trial starts
... The Octopus trial - so-called because it is a multi-arm, multi-stage trial - is being run by Prof Jeremy Chataway, from the National Hospital for Neurology and Neurosurgery UCLH in London, with £13m in funding from the UK s MS Society...
Kenya school collapse: Seven dead and dozens injured in Nairobi
... The Kenyan Red Cross transferred some children to the Kenyatta National Hospital...
Ayrshire man goes from heart patient to Ironman in 16 months
... He read the story while recovering from life-saving heart surgery at the Golden Jubilee National Hospital in Clydebank and started training six weeks later...
New Alzheimer's drug slows disease by a third
By James GallagherHealth and science correspondent
We could be entering the era of Alzheimer's treatments, after The Second drug in under a year has been shown to slow the Disease .
Experts said we were now " on the cusp" of drugs being available, something that had recently seemed " impossible".
The Company Eli Lilly has reported its drug - donanemab - slows the pace of Alzheimer's by about a third.
However two volunteers, and possibly a third, died as a result of dangerous swelling in The Brain .
Sticky gunkDonanemab works in the same way as lecanemab, when it was the proven to slow the Disease .
Both are antibodies like those The Body makes to attack viruses. But these are engineered to clear a sticky gunk from The Brain , called beta amyloid.
Amyloid builds up in the spaces between brain cells, forming distinctive plaques that are one of The Hallmarks of Alzheimer's.
" The decades-long battle to find treatments that change Alzheimer's Disease is changing, " Dr Cath Mummery, the clinical lead for the cognitive-disorders clinic at the UK's National Hospital for Neurology and Neurosurgery, said.
" We Are now entering The Time of Disease modification, where we might realistically hope to treat and maintain someone with Alzheimer's Disease , with long-term Disease management rather than palliative and supportive care. "
The full details of Eli Lilly 's trial have yet to be published - But it has revealed The Key findings:
However, brain swelling was a common side-effect in up to a third of patients.
It was mostly mild or asymptomatic despite being detected on brain scans - But 1. 6% developed dangerous brain swelling, with Two Deaths directly attributed to it and a third volunteer dying after such a case.
" We Are encouraged by the potential clinical benefits that donanemab may provide, although like many effective treatments for debilitating and fatal diseases, there are associated risks that may be serious and life-threatening, " Eli Lilly group vice-president of neuroscience research and development Dr Mark Mintun said.
The Company said it would begin The Process of having its drug approved for use in hospitals in The Next few months.
Dr Liz Coulthard, from the University of Bristol, said there were " significant side-effects" and a lack of long-term data But the drug could " help people live well with Alzheimer's for longer".
'Thought impossible'Having two drugs slow the Disease by targeting amyloid in The Brain has also convinced scientists they are on The Right track after decades of misery and failure.
" This should dispel any lingering doubts about this approach, " Prof John Hardy, from the UK Dementia Research Institute , whose work led to the idea of targeting amyloid, 30 years ago, said. " Having two drugs is great for competition. "
Dr Susan Kolhaas, from Alzheimer's Research UK, said: " We're now on the cusp of a first generation of treatments for Alzheimer's Disease , something that many thought impossible only a decade ago. "
However, these drugs appear to work in only the earliest stages of the Disease - before The Brain is too damaged.
And if they are approved in the UK, it would still take a revolution in how the Disease is diagnosed to make a difference.
Only 1-2% of people have either brain scans or a spinal-fluid analysis to determine whether they actually have Alzheimer's or another form of dementia Against Which the drugs would be useless.
.
Related TopicsSource of news: bbc.com
